Special Investigation Of Xalkori For Nsclc (Regulatory Post Marketing Commitment Plan)
Phase of Trial: Phase IV
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 26 Mar 2018 Status changed from active, no longer recruiting to completed.
- 05 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 05 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.